statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Why Recursion Pharmaceuticals Stock Is Tumbling Thursday

Recursion announced that it intends to offer and sell 30,769,230 shares of its common stock for $6.50 per share in an underwritten public offering. The clinical-stage biotech company also said it...

Recursion Pharmaceuticals Stock Is Diving Wednesday: What's Going On?

After the market close on Wednesday, Recursion said it intends to offer and sell $200 million worth of its common stock in an underwritten public offering. All of the shares are being offered by...

Recursion Pharmaceuticals Stock Is Moving Tuesday: What's Happening?

Shares of clinical stage biotech company Recursion Pharmaceuticals Inc (NASDAQ:RXRX) are trading higher Tuesday. The company's CEO Chris Gibson joined CNBC for an interview ahead of a presentation...

What's Going On With Recursion Pharmaceuticals Stock Monday?

Recursion Pharmaceuticals shares traded higher Monday after the company provided updated guidance and partnership updates at its Investor Day. The stock is continuing to move higher after hours amid...

Recursion Pharmaceuticals Stock Surges 10% As Nvidia-Powered Supercomputer Completion Sparks Investor Optimism

Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) made waves Monday afternoon not only with the announcement of its groundbreaking BioHive-2 supercomputer but also with a notable surge in its stock...

Recursion Pharmaceuticals CEO Chris Gibson goes one-on-one with Jim Cramer

Recursion Pharmaceuticals CEO Chris Gibson goes one-on-one with Jim Cramer...

Demystifying Recursion Pharmaceuticals: Insights From 4 Analyst Reviews

Latest Ratings for RXRX
 DateFirmActionFromTo Mar 2022SVB LeerinkDowngradesOutperformMarket Perform Dec 2021SVB LeerinkMaintainsOutperform Sep 2021BerenbergInitiates Coverage OnBuy
 View More...

Nvidia-Backed Recursion Pharmaceuticals Stock Is Up On Q1 Earnings: Everything You Need To Know

Recursion reported first-quarter revenue of $13.491 million, which beat analyst estimates of $12.65 million, according to Benzinga Pro. The company reported a quarterly loss of 39 cents per share...

(RXRX) - Analyzing Recursion Pharmaceuticals's Short Interest

AI in Healthcare: Unveiling the Future with a 42.20% CAGR Through 2029

AI in Healthcare: Unveiling the Future with a 42.20% CAGR Through 2029 AI in Healthcare: Unveiling the Future with a 42.20% CAGR Through 2029 PR Newswire VANCOUVER, BC, April 25, 2024 USA News Group...

Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company that combines automation, artificial intelligence, machine learning, and in vivo validation capabilities to discover novel medicines. Its Recursion operating system enables advanced machine learning approaches to reveal drug candidates, mechanisms of action, novel chemistry, and potential toxicity, with the eventual goal of decoding biology and advancing new therapeutics that radically improve people's lives. The company was founded by Blake Borgeson, Christopher C. Gibson, and Dean Y. Li on November 5, 2013 and is headquartered in Salt Lake City, UT.

Volume	2.96M
52-Wk High	$15.74
52-Wk Low	$4.97

RXRX Recursion Pharmaceuticals Inc - Ordinary Shares - Class A

About

Feed

News

Sentiment

Earnings

Fundamentals